NuGene International, Inc. Reports Financial Results for the Three Months Ended March 31, 2015

IRVINE, CA--(Marketwired - May 18, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, announced today the filing of its Quarterly Report for the three months ended March 31, 2015 with the U.S. Securities and Exchange Commission.

"We achieved important milestones in the first quarter of 2015," stated Ali Kharazmi, CEO of NuGene. "During this quarter we:

• Reported $481,360 of sales
• Relocated to an 11,000 square foot office, research, manufacturing and assembly location in Orange County, California
• Invested approximately $83,000 in laboratory and office equipment and leasehold improvements to our new facility
• Generated all first quarter revenues from our NuGene product lines, effectively diversifying our revenue streams away from affiliated transactions
• Formed NuGene BioPharma for biopharmaceutical development
• Acquired SkinGuardian® as a platform to further develop our advanced skin and wound treatments
• Continued to attract industry luminaries to our Advisory Board
• Launched NuGene kathy ireland® branded products promotion on nationally syndicated television show (Extra)
• Initiated development of mass retail sales model for NuGene kathy ireland® brand
• Commenced the development of an 'in-house' sales team."
  
  

For more information and the full quarterly report, please visit the Investors section of www.nugene.com.

About NuGene International, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications and inventions. NuGene's goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 10-Q filed with the Commission on May 15, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

* News and content distribution powered by 1-800-PublicRelations, Inc. - 1800pr.com